Ncardia Services B.V.
A leading pioneer in leveraging iPSC innovation for drug discovery. The catalyst with the requisite iPSC know-how and experience to empower innovators in drug discovery to advance their science relentlessly, consistently and efficiently. For the past decade at Ncardia, our team has collaborated with a broad array of clients to forge ahead their drug discovery programs for cardiovascular and neurological diseases. Throughout that process, they’ve leveraged our human translational models to increase their probability of downstream success in the drug discovery and development process. At Ncardia, we lean into advanced technology, so we can provide the right solutions: disease modeling, large-scale manufacturing, assay development and screening.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)
- Year Founded:
Predict future safety and efficacy more efficiently
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC-based drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas. By enabling our clients to get to crucial decision points faster and with higher confidence, we help them exclude non-valuable compounds and select the most promising candidates earlier.
Proven, integrated drug discovery services from Ncardia
By continually cultivating a special expertise in iPSC biology, Ncardia has developed an integrated drug discovery platform that primes your team for a higher probability for downstream success that helps avoid costly attrition.
To enable biopharmaceutical companies in drug discovery to accelerate their drug discovery pipelines through the integration of human iPSC technologies
Perfecting the full potential of iPSCs to transform drug discovery in human healthcare
Meet the Ncardia Team
At Ncardia, our innovative technologies are in the hands of a diverse team of expert scientists and strategists who are singularly focused on iPSCs – and who are committed to helping our clients solve critical problems, embrace bold yet highly strategic risks, and unlock the full potential of their discoveries.
Our Milestones To-Date
Our organization was founded with the singular focus to help realize the potential of iPSCs to advance human health. Our belief in the science behind this technology has inspired us to develop our own iPSC-derived cell models, to invest in next-generation drug discovery technologies, and, where it merits, to spin off our work into entirely new business entities.
Cellistic, an affiliate company focused on iPSC-based cell therapy, is formed to capitalize on Ncardia’s large-scale manufacturing expertise and proven processes in iPSC differentiation
$60 million investment as part of a strategic partnership with Kiniciti to expand our drug discovery offerings
Launch of Ncardia’s large-scale iPSC manufacturing platform
Ncardia was formed in August 2017 following an acquisition by Pluriomics
First iPSC-based drug discovery screening activities performed
Formulation of Pluriomics
Formulation of Pluriomics, an iPSC-derived research product company, by Stefan Braam and Herman Spolders, together with the scientific founders Prof. Dr. Mummery and Prof. Dr. Passier.